Cargando…
A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A retrospective study
Intravesical Bacillus Calmette Guerin (BCG) is the gold standard therapy for intermediate/high-risk non-muscle invasive bladder cancer (NMIBC). However, the response rate is ~60%, and 50% of non-responders will progress to muscle-invasive disease. BCG induces massive local infiltration of inflammato...
Autores principales: | VILLOLDO, GUSTAVO MARTÍN, POMBO, MARÍA TERESA, ARIS, MARIANA, CHEMI, JOAQUÍN, MANDÓ, PABLO, NAGARAJU, SUPRIYA, CAMEAN, JUAN, BURIONI, ADRIÁN, EGEA, DEBORAH, AMAT, MORA, MELLADO, JOSÉ LEÓN, MORDOH, JOSÉ, VILLARONGA, ALBERTO, BARRIO, MARÍA MARCELA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tech Science Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208021/ https://www.ncbi.nlm.nih.gov/pubmed/37304240 http://dx.doi.org/10.32604/or.2023.028163 |
Ejemplares similares
-
Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021) -
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Disseminated Bacillus Calmette-Guérin Infection and Immunodeficiency
por: Bernatowska, Ewa Anna, et al.
Publicado: (2007) -
Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018) -
Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021)